Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
BACKGROUND
Patients with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for ventricular arrhythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement. Device-based management of asymptomatic patients is controversial. ICD therapy is associated with high rates of inappropriate shocks and device-related complications.


OBJECTIVE
The objective of this study was to investigate clinical features, management, and long-term follow-up of ICD therapy in patients with Brugada syndrome.


METHODS
Patients presenting with spontaneous or drug-induced Brugada type 1 electrocardiographic findings, who underwent ICD implantation and continuous follow-up at a single institution, were eligible for this study.


RESULTS
A total of 176 consecutive patients were included. During a mean follow-up period of 83.8 ± 57.3 months, spontaneous sustained VAs occurred in 30 patients (17%). Eight patients (4.5%) died. Appropriate ICD shocks occurred in 28 patients (15.9%), and 33 patients (18.7%) had inappropriate shocks. Electrical storm occurred in 4 subjects (2.3%). Twenty-eight patients (15.9%) experienced device-related complications. In multivariate Cox regression analysis, aborted sudden cardiac death and VA inducibility on electrophysiologic studies were independent predictors of appropriate shock occurrence.


CONCLUSIONS
ICD therapy was an effective strategy in Brugada syndrome, treating potentially lethal arrhythmias in 17% of patients during long-term follow-up. Appropriate shocks were significantly associated with the presence of aborted sudden cardiac death but also occurred in 13% of asymptomatic patients. Risk stratification by electrophysiologic study may identify asymptomatic patients at risk for arrhythmic events and could be helpful in investigating syncope not related to VAs. ICD placement is frequently associated with device-related complications, and rates of inappropriate shocks remain high regardless of careful device programming.
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium. Electronic address: giulioconte.cardio@gmail.com.
Giulio
G
Conte
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Juan
J
Sieira
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Giuseppe
G
Ciconte
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Carlo
C
de Asmundis
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Gian-Battista
GB
Chierchia
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Giannis
G
Baltogiannis
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Giacomo
G
Di Giovanni
Cardiac Surgery Department, UZ Brussel-VUB, Brussels, Belgium.
Mark
M
La Meir
Cardiac Surgery Department, UZ Brussel-VUB, Brussels, Belgium.
Francis
F
Wellens
Cardiac Surgery Department, UZ Brussel-VUB, Brussels, Belgium.
Jens
J
Czapla
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Kristel
K
Wauters
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Moises
M
Levinstein
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Yukio
Y
Saitoh
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Ghazala
G
Irfan
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Justo
J
Julià
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Gudrun
G
Pappaert
Heart Rhythm Management Centre UZ Brussel-VUB, Brussels, Belgium.
Pedro
P
Brugada
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001530:Belgium / Q000453:epidemiology; D053840:Brugada Syndrome / Q000401:mortality / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003645:Death, Sudden / Q000517:prevention & control; D017147:Defibrillators, Implantable / Q000009:adverse effects; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D013015:Sotalol / Q000627:therapeutic use; D013575:Syncope / Q000517:prevention & control; D017180:Tachycardia, Ventricular / Q000517:prevention & control; D013997:Time Factors; D055815:Young Adult
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D013015:Sotalol
Brugada syndrome; implantable cardioverter-defibrillator; sudden cardiac death; ventricular arrhythmias